Participants 0 98 3
Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis
Participants 353 647 5
Patients ages ≥18 years with active RA with an inadequate response to ≥1 tumor necrosis factor inhibitor (TNFi) and receiving stable background methotrexate were randomized 2:2:1:1 to tofacitinib 5 mg or 10 mg twice daily, or placebo advanced to tofacitinib 5 mg or 10 mg twice daily at mon
Participants 1854 1921 3
 in patients with active RA and a previous inadequate response to T
